Nitroglycerin sublingual - Pohl-Boskamp

Drug Profile

Nitroglycerin sublingual - Pohl-Boskamp

Alternative Names: GoNitro; Nitrolingual Pumpspray

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pohl-Boskamp
  • Class Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris
  • Phase II Peripheral arterial occlusive disorders

Most Recent Events

  • 20 Apr 2017 Phase-II clinical trials in Peripheral arterial occlusive disorders (In adults, In the elderly) in Germany (Sublingual) (EudraCT2016-004460-19)
  • 27 Sep 2016 Launched for Angina pectoris in USA (Sublingual, Powder)
  • 08 Jun 2016 Registered for Angina pectoris in USA (Sublingual, powder) (FDA website; June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top